OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling